VaxiPatch, a Novel Vaccination System Comprised of Subunit Antigens, Adjuvants and Microneedle Skin Delivery: An Application to Influenza B/Colorado/06/2017
Posted by Adam Awdish on
Turkey Red Blood Cells Packed 5% and Single Donor Human Red Blood Cells Washed from Innovative Research was used in the following study:
Thomas J.Ellison, George C.Talbott, Daniel R.Henderson
Vaccine
July 31, 2020
Vaccination is widely regarded as the most cost-effective form of medicine. Vaccines are usually lyophilized products reconstituted with water or saline and delivered via intramuscular injection (IM). Despite the popularity of IM injections, intradermal (ID) injection has long been known to offer advantages, most notably the fact the ID injections typically only require a fraction of the dose of required for its IM counterpart to be effective.
Although vaccines are effective, 20% of the US adult population avoids vaccines due to needle phobia; Painless delivery could increase vaccine acceptance and use. Further, microneedle skin patch vaccines that utilize ID injection technology can reduce the cost of vaccination.
Researchers in this study introduced VaxiPatch, a novel vaccination system comprised of subunit glycoprotein vaccine antigens, adjuvants and dermal delivery. The researchers injected Sprague Dawley rats with VaxiPatches containing 0.3 µg of rHA, 0.5 µg QS-21 and 0.2 µg 3D - (6-acyl) PHAD and dye, resulting in antigen-specific IgG titers 100-fold higher than 4.5 µg of FluBlok (p = 0.001) delivered intramuscularly. Further study suggests that formulated virosomal antigens retain activity for at least two months at 60° C. The researchers concluded that a room-temperature-stable vaccination kit such as VaxiPatch has the potential to increase vaccine use and compliance globally.
Related products available from Innovative Research also include:
Single Donor Human Whole Blood